Clinical Trial Search

Primary: Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to Adverse Events (AEs) — 1 incidence

Primary: Description of the Clinical and Epidemiological Profile of Patients With Infection — 92; 26; 25; 21 Participants

Primary: Percentage of Participants With Clinical Improvement in the 3 General Categories of Pain, Inflammation, and Limb Function Based on the Investigator's Overall Assessment…

Primary: Clinical Success at 6 Months — 18; 9; 3 Participants

Primary: Systemic Vancomycin Level - Start of Case — 27.98; 0 ug/mL

Primary: Number of Participants With Treatment-Emergent Adverse Events (Safety and Tolerability) Following Multiple Doses of Intravenous AP-Sa02. — 17; 10; 6; 2 number of…

Primary: Number of Participants With the Presence of Post-Operative Infection — 2; 2 Participants

Primary: T2* Relaxation Time of Bone Sarcomas and Osteomyelitis Subjects — 7.3; 7.7 milliseconds

Primary: Incidence of Surgical Site Infection (SSI) Relating to Intramedullary Nailing for Fixation of Diaphyseal Femoral and Tibial Fractures — 26; 195 Participants

Primary: Eradication of Staphylococcus Aureus (SA) Carriage at All 4 Body Sites Tested. — 13; 41 Participants

Primary: Number of Blood Samples With High Levels of Absorbance Via ELISA for Patients (Greater Than 1.5 Ratio Compared to Control Human Serum) — 48; 53 blood draw samples

Primary: Percentage of Participants With Clinical Response at Day 42 in the Clinically Evaluable (CE) Population — 97.0; 87.5; 0.0; 12.5 percentage of participants

Primary: Number of Patients With or Without Overall Success at the Post-treatment Evaluation (PTE) Visit — 132; 136; 57; 62 Participants

Primary: Any Creatine Phosphokinase (CPK) Elevation > 500 Units Per Liter (U/L) — 4; 5; 2 Participants

Primary: Shift From Baseline in Distortion Product Otoacoustic Emission at TOC Visit — 2; 1; 0; 0 Participants

Primary: Number of Participants With One or More Adverse Events (AEs) — 15; 6; 12; 9 Participants

Primary: Quantify the Tolerability of Tedizolid for Bone and Joint Infections, Both Hardware and Non-hardware Associated — 0; 0 participants

Primary: Number of Participants With a Pathogen Identified by the Initial Karius Test (IP1) and Standard Culture Methods — 23; 26; 15 Participants

Primary: Desirability of Outcome Ranking (DOOR) — 49; 49; 34; 37 Participants

Primary: Number of Participants Who Experienced Dose-limiting Toxicities — 0; 0; 0; 0 participants

Primary: Change in Eczema Area and Severity Index (EASI)Scores According to Location — -1.06; -0.57; -4.94; -0.88 Change in EASI Score

Primary: Occurrence of Post-chemotherapy Bacteremia — 22; 81 Participants

Primary: Cure Rate — 207; 209 Participants

Primary: Number of Participants With Adverse Events — 5; 4; 1; 6 participants

Primary: Clinical Outcome in Participants With Baseline Methicillin Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for PP Population — 95; 81; 70; 93 Participants…

Primary: Number of Participants With Eradiction of S. Aureus From the Oropharyngeal at 7 Days — 18; 7 Participants

Primary: Clinical Response (Cure, Failure, or Indeterminate) as Determined by the Investigator Based the Presence or Absence of Clinical Signs and Symptoms Associated With…

Primary: Number of Participants With Tissue Samples Identified With Bacterial DNA According to Highly Sensitive Bacterial Assays — 10; 24; 20 Participants

Primary: Number of Participants With Solicited Adverse Events (AEs) During Days 1-7 — 2; 1; 17; 4 participants

Primary: Percentage of Participants With Clinical Success — 85; 69 percentage of participants — p=0.009